VRX - Valeant Pharmaceuticals International, Inc.

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous closeN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's rangeN/A - N/A
52-week rangeundefined - undefined
VolumeN/A
Avg. volumeN/A
Market capN/A
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018
    Motley Fool4 months ago

    Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018

    A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.

  • Valeant Pharmaceuticals before Its Q2 2018 Earnings
    Market Realist4 months ago

    Valeant Pharmaceuticals before Its Q2 2018 Earnings

    Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.

  • Analyst Recommendations for Valeant Pharmaceuticals in July
    Market Realist4 months ago

    Analyst Recommendations for Valeant Pharmaceuticals in July

    In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.

  • Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options

    Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.

  • Why Has Valeant Stock Fallen in June?
    Market Realist5 months ago

    Why Has Valeant Stock Fallen in June?

    Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.

  • Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
    Zacks5 months ago

    Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

    Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

  • Company News For Jun 19, 2018
    Zacks5 months ago

    Company News For Jun 19, 2018

    Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA

  • Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today
    Motley Fool5 months ago

    Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today

    The FDA has dealt the company some disappointing news on one of its late-stage drugs.

  • What Happened in the Stock Market Today
    Motley Fool5 months ago

    What Happened in the Stock Market Today

    On a day stocks fell on trade worries, Google announced a big investment, and Valeant Pharmaceuticals got a rejection from the FDA.

  • Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
    Zacks5 months ago

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

  • Drug Stocks: The Next Hot Industry or Value Traps?
    Zacks5 months ago

    Drug Stocks: The Next Hot Industry or Value Traps?

    These 5 stocks look dirt cheap but is it too good to be true?

  • Valeant Pharmaceuticals’ Valuation on June 8
    Market Realist5 months ago

    Valeant Pharmaceuticals’ Valuation on June 8

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.

  • What Are Valeant’s Key Developments since May?
    Market Realist5 months ago

    What Are Valeant’s Key Developments since May?

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a 9% decrease in its operating revenues to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. On June 1, Valeant entered into a fourth amended and restated credit and guarantee agreement to refinance its secured revolving and term loan credit facilities. The company also closed the offering of 8.500% senior notes due in 2027 by a wholly owned indirect subsidiary.

  • Analyzing Valeant’s Quarterly Earnings and Estimates
    Market Realist5 months ago

    Analyzing Valeant’s Quarterly Earnings and Estimates

    Valeant Pharmaceuticals (VRX) reported a GAAP net loss of ~$2.7 billion during the first quarter—compared to the GAAP net income of ~$628 million during the first quarter of 2017. Also, the GAAP EPS was negative at -$7.68. The company reported a loss during the first quarter—compared to the GAAP EPS of $1.79 during the first quarter of 2017.

  • Valeant’s Quarterly Revenue Trend and Estimates
    Market Realist5 months ago

    Valeant’s Quarterly Revenue Trend and Estimates

    Valeant Pharmaceutical’s (VRX) revenues decreased ~5.4% to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. Valeant met Wall Street analysts’ revenue estimates and reported revenues of ~$1.995 billion—compared to estimates of ~$1.944 billion during the first quarter. Valeant reported organic growth of 2% in total revenues during the first quarter.

  • Analysts’ Recommendations for Valeant in June
    Market Realist5 months ago

    Analysts’ Recommendations for Valeant in June

    Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter.